Candriam S.C.A. Has $26.36 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• Candriam S.C.A. increased its holdings in Ultragenyx Pharmaceutical Inc. by 8.0%, purchasing an additional 53,760 shares, bringing its total ownership to approximately 0.77% valued at $26,361,000.
• A variety of institutional investors have also boosted their stakes in Ultragenyx, with Capital Fund Management S.A. and EntryPoint Capital LLC raising their holdings by 40.5% and 58.3%, respectively.
• Ultragenyx Pharmaceutical's stock recently experienced a 0.8% increase in value, with current trading at $29.36 and analysts projecting an average price target of $81.50.

Candriam S.C.A. raised its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 8.0% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 728,017 shares of the biopharmaceutical company's stock after purchasing an additional 53,760 shares during the quarter. Candriam S.C.A. owned approximately 0.77% of Ultragenyx Pharmaceutical worth $26,361,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. GAMMA Investing LLC lifted its position in shares of Ultragenyx Pharmaceutical by 76.2% in the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 323 shares during the last quarter. ANTIPODES PARTNERS Ltd acquired a new stake in shares of Ultragenyx Pharmaceutical in the first quarter valued at approximately $57,000. Headlands Technologies LLC acquired a new stake in shares of Ultragenyx Pharmaceutical in the first quarter valued at approximately $59,000. Covestor Ltd lifted its position in shares of Ultragenyx Pharmaceutical by 86.8% in the first quarter. Covestor Ltd now owns 1,711 shares of the biopharmaceutical company's stock valued at $62,000 after buying an additional 795 shares during the last quarter. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $82,000. 97.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

RARE has been the subject of a number of research reports. Wells Fargo & Company cut their target price on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a research note on Thursday, July 10th. William Blair initiated coverage on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, May 28th. They set an "outperform" rating and a $65.00 target price for the company. Canaccord Genuity Group cut their target price on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating for the company in a research note on Friday, August 8th. HC Wainwright upgraded shares of Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 target price for the company in a research note on Monday, July 28th. Finally, Cantor Fitzgerald dropped their price target on Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an "overweight" rating for the company in a report on Wednesday, August 6th. Eleven research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical presently has a consensus rating of "Moderate Buy" and an average price target of $81.50.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ:RARE traded down $0.5450 during mid-day trading on Monday, hitting $29.2350. 762,365 shares of the stock were exchanged, compared to its average volume of 1,294,734. The firm's 50-day simple moving average is $31.69 and its 200 day simple moving average is $35.65. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $25.81 and a fifty-two week high of $60.37. The stock has a market capitalization of $2.82 billion, a price-to-earnings ratio of -5.30 and a beta of 0.25.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $0.10. The firm had revenue of $166.50 million during the quarter, compared to analysts' expectations of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The company's quarterly revenue was up 13.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.52) EPS. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of Ultragenyx Pharmaceutical stock in a transaction on Friday, June 20th. The stock was sold at an average price of $37.39, for a total value of $89,922.95. Following the completion of the transaction, the director directly owned 15,344 shares of the company's stock, valued at $573,712.16. The trade was a 13.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.50% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.